XML 16 R4.htm IDEA: XBRL DOCUMENT v3.26.1
Condensed Consolidated Statements of Operations - Unaudited - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Revenue $ 0 $ 0 $ 36,839 $ 0
Operating expenses:        
Research and development 8,770 4,103 17,748 6,933
General and administrative 5,160 3,618 9,758 7,291
Total operating expenses 13,930 7,721 27,506 14,224
Operating (loss) income (13,930) (7,721) 9,333 (14,224)
Interest income 812 275 1,650 606
Net (loss) income before income taxes and noncontrolling interest (13,054) (7,380) 11,080 (13,597)
Income tax provision 0 0 0 0
Net (loss) income before noncontrolling interest (13,054) (7,380) 11,080 (13,597)
Less: net loss attributable to noncontrolling interest 0 (1,334) 0 (2,459)
Net (loss) income attributable to vTv Therapeutics Inc. (13,054) (6,046) 11,080 (11,138)
Net (loss) income attributable to vTv Therapeutics Inc. common shareholders (13,054) (6,046) 11,080 (11,138)
Nonrelated Party        
Operating expenses:        
Other income (expense), net 29 12 38 (5)
Related Party        
Operating expenses:        
Other income (expense), net $ 35 $ 54 $ 59 $ 26
Class A Common Stock        
Operating expenses:        
Basic net (loss) income per share of vTv Therapeutics Inc. Class A common stock (in usd per share) $ (1.05) $ (0.92) $ 0.89 $ (1.69)
Basic weighted average number of vTv Therapeutics Inc. Class A common stock (in shares) 12,409,316 6,587,070 12,409,297 6,584,969
Diluted net (loss) income per share of vTv Therapeutics Inc. Class A common stock (in usd per share) $ (1.05) $ (0.92) $ 0.76 $ (1.69)
Diluted weighted average number of vTv Therapeutics Inc. Class A common stock (in shares) 12,409,316 6,587,070 14,541,788 6,584,969